IPO FILING - Transkaryotic Therapies Inc . [START_ENT] WASHINGTON [END_ENT] 1996-08-27  Company Name Transkaryotic Therapies Inc  Nasdaq Stock symbol TKTX  Estimated price range $ 13 - $ 15 / shr  Total shares to be offered 2.5 million  Shrs offered by company 2.5 million  Shrs outstanding after ipo 16,668,560  Lead Underwriter Morgan Stanley and Co Inc  Underwriters over-allotment 375,000 shrs Shares to be purchased by Hoechst Marion Roussel Inc 357,143 Business : developed two proprietary technology platforms , gene activation and gene therapy .  Use of Proceeds : Research , preclinical and clinical product development , and general corporate purposes .  Financial Data in 000s : 1995 1994  - Revenue $ 15,400 $ 10,000  - Net Income ( loss ) $ 2,074 ( $ 3,422 )
Washington, D.C.